Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, Suite 1350, Cambridge, Massachusetts
Fiscal year end
December 31
Former names
Cullinan Oncology, Inc. (to 4/2/2024), Cullinan Management, Inc. (to 2/22/2021), Cullinan Oncology, LLC (to 1/6/2021)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.04 K % +35.3%
Debt-to-equity 5.54 % -17.9%
Return On Equity -28.7 % -342%
Return On Assets -27.1 % -345%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.1 M shares +9.51%
Common Stock, Shares, Outstanding 43.1 M shares +9.46%
Entity Public Float 374 M USD -0.4%
Common Stock, Value, Issued 4 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 43 M shares +5.73%
Weighted Average Number of Shares Outstanding, Diluted 43 M shares +5.73%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 127 M USD +6.02%
General and Administrative Expense 44.2 M USD +3.39%
Operating Income (Loss) -171 M USD -250%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -169 M USD -212%
Income Tax Expense (Benefit) -14.1 M USD -134%
Net Income (Loss) Attributable to Parent -132 M USD -303%
Earnings Per Share, Basic -3.13 USD/shares -339%
Earnings Per Share, Diluted -3.13 USD/shares -354%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 74.2 M USD -39.2%
Other Assets, Current 3.9 M USD
Assets, Current 446 M USD +11.7%
Other Long-term Investments 15.5 M USD -49.5%
Property, Plant and Equipment, Net 913 K USD -26.3%
Operating Lease, Right-of-Use Asset 2.34 M USD -38.8%
Other Assets, Noncurrent 460 K USD +0.22%
Assets 449 M USD -12.7%
Accounts Payable, Current 3.71 M USD +82.5%
Accrued Liabilities, Current 16.9 M USD -8.11%
Liabilities, Current 21.9 M USD -16.2%
Operating Lease, Liability, Noncurrent 1.84 M USD -42%
Liabilities 23.8 M USD -19%
Accumulated Other Comprehensive Income (Loss), Net of Tax -331 K USD +73.3%
Retained Earnings (Accumulated Deficit) -238 M USD -125%
Stockholders' Equity Attributable to Parent 426 M USD -12.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 426 M USD -12.4%
Liabilities and Equity 449 M USD -12.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2 M USD +25%
Net Cash Provided by (Used in) Financing Activities 1.09 M USD -39.4%
Net Cash Provided by (Used in) Investing Activities 13 M USD -14.7%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 43.1 M shares +9.46%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 32 K USD
Deferred Tax Assets, Valuation Allowance 87.4 M USD +86.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 88.3 M USD +83.3%
Operating Lease, Liability 3.17 M USD -32.9%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -131 M USD -295%
Lessee, Operating Lease, Liability, to be Paid 3.56 M USD -35.7%
Property, Plant and Equipment, Gross 1.34 M USD +2.45%
Operating Lease, Liability, Current 1.33 M USD -14.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 871 K USD -40.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.46 M USD -15.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 5.4 M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 391 K USD -51.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 872 K USD -40.3%
Deferred Tax Assets, Operating Loss Carryforwards 14.4 M USD +37.1%
Preferred Stock, Shares Issued 648 K shares 0%
Current Income Tax Expense (Benefit) 14.1 M USD -66.5%
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 872 K USD
Preferred Stock, Shares Outstanding 648 K shares
Depreciation, Depletion and Amortization 76 K USD +5.56%
Deferred Tax Assets, Net of Valuation Allowance 914 K USD -34.8%
Share-based Payment Arrangement, Expense 31.4 M USD +9.62%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%